Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors. - Wikidata - awgldk - TriplyDB

Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors.

Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors.

http://www.wikidata.org/entity/Q38096411

about

Bispecific antibodies and their applications AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells Entire CD3ε, δ, and γ humanized mouse to evaluate human CD3-mediated therapeutics.Multi-specific antibodies for cancer immunotherapy.T-cell-associated cellular immunotherapy for lung cancer.Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology.Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors.Current progress in innovative engineered antibodies.CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy.Development of a Target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agents Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells

P2860

Q26774024-9C4EBA46-2F0F-4307-B9EF-79BC86B5F877 Q30637447-ED058EC2-2E07-4553-BE43-1282EDA596AE Q34817365-B2582953-B328-46F0-A9EC-3381E6C610D4 Q36963057-30648A6C-DF1E-4E61-BB3F-AE80D81BFE3C Q37734869-00B741E5-D38B-4731-8BE2-3CFC1910FAF7 Q38196723-59B748CF-3571-4B26-9B1E-CC04E4953F40 Q38266198-A6C84DD3-1608-448B-8731-06240EB78DCA Q38400420-EF6B7A2B-CF96-4942-9F85-BC8EE6E91DA5 Q38525034-EF6AAA4A-B885-4447-9F29-E241C572206E Q40077818-A09798B2-B796-4F9D-87B2-D700C2035E92 Q52731744-DB640D08-3746-4D2F-A347-12A40094ED08 Q58726545-C1D8D12A-5563-41DD-9B48-57A7A2678E88 Q59134014-74A08C1E-55D4-4338-AC1A-B05FC33AABB6

P2860

Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors.

http://www.wikidata.org/entity/Q38096411

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Redirection of T-cell effector ...... nd chimeric antigen receptors.

@en

type

label

Redirection of T-cell effector ...... nd chimeric antigen receptors.

@en

prefLabel

Redirection of T-cell effector ...... nd chimeric antigen receptors.

@en

P1433

Q38096411-32AA38C9-2482-4FE6-928F-D64ACAE3F9A5

P1476

Q38096411-F636B398-094E-4024-AD3D-5A1025998639

P2093

Q38096411-5504055F-C94A-414B-AF32-DA31BD385CEC

Q38096411-60338D32-A275-4E36-95E0-BF5B3A7D29E7

Q38096411-A7CA6A32-958C-44C9-A078-E08A6BFA00BA

P2860

Q38096411-03DE19EF-30E9-4240-A9E8-DAECA4B3C5F2

Q38096411-090CE065-F73B-4773-90B3-A5A54DEAEFC2

Q38096411-0A7B9FAA-9D7E-469A-90AB-097A5472D720

Q38096411-0A7C115E-61C9-4CB4-BE29-D1B13AB7EC70

Q38096411-1753089B-DF76-4C6F-929D-09504BB2421C

Q38096411-20028FEC-9E02-4F29-95CD-3B5043B254E2

Q38096411-2AA05739-387B-4171-B08E-E496761F8EFB

Q38096411-32AFA953-8A99-4012-9FA6-5A0419F82E1F

Q38096411-34B05F34-6819-4E97-AC69-59CDA23BABE3

Q38096411-377589A7-11E5-4CAE-9004-D01438099B50

P304

Q38096411-DA8DCB1B-CD72-4D4D-AFD3-D2B0105539F4

P31

Q38096411-43FDDB68-81F1-44B4-9691-6C84C5B98ADF

P356

Q38096411-AB7E7B11-F7B5-46DE-9FE6-BFCB4D84ACF8

P407

Q38096411-8E3B1B7A-50D0-4AC0-AE6C-B3173C25EEA7

P433

Q38096411-DDCF2FD1-A749-4E51-9F28-AE590DCD5E12

P478

Q38096411-E5607BEB-C066-476B-943E-BF758B52EF3F

P50

Q38096411-2B630879-BFAF-44EA-BCB0-2CD010BFE34A

Q38096411-FF231189-C876-4851-87C9-E29056C55182

P577

Q38096411-F74B257F-A922-4AE7-A249-348EFE485920

P698

Q38096411-75813F44-9804-497F-919B-6CCDD89716E5

P356

P1433

Future Oncology

P1476

Redirection of T-cell effector ...... nd chimeric antigen receptors.

@en

P2093

Alessandro Satta

http://www.w3.org/2001/XMLSchema#string

Fabio Turatti

http://www.w3.org/2001/XMLSchema#string

Silvana Canevari

http://www.w3.org/2001/XMLSchema#string

P2860

Continuous cultures of fused cells secreting antibody of predefined specificity

Antibody therapy of cancer

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies

Immunotherapeutic perspective for bispecific antibodies.

A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor.

In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)

Introduction to current and future protein therapeutics: a protein engineering perspective.

P304

527-539

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.12.203

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Delia Mezzanzanica

Mariangela Figini

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23560375

http://www.w3.org/2001/XMLSchema#string